Abstract
(Atopic) eczema is commonly treated with oral corticosteroids (OCS), which increase fracture risk. Fracture-preventive medications, including bisphosphonates, are recommended to counter the negative effects of OCS on bone health when individuals are prescribed >=450mg prednisolone equivalent dose (PED) in 6 months. People with eczema are prescribed OCS in different patterns (e.g., continuously or intermittently). We hypothesised people receiving intermittent OCSs were less likely to receive adequate fracture-preventive care than people receiving the same cumulative OCS dose continuously.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
